Mechanistic Cell Biology

Biological Pathways and Genetic Drivers

In Vitro Proof of Concept Studies

Sound in vitro mechanism of action data are needed to progress your compound towards the clinic. The right assay format is determined by your anti cancer drug candidate and its target. We support you in determining the effects of your compound on selected biological pathways.

  • Expression analysis by quantitative real-time PCR, flow cytometry or immuno blot

  • Modulation of expression by siRNA

  • Generation of resistant cell lines

  • Confirmation of genetic drivers by DNA sequencing and qPCR

  • Apoptosis assays, readout Caspase 3/7 or flow cytometry

  • Colony formation assays

  • Assays based on fluorescence, chemiluminescence, TR-FRET or Alpha technology

  • Choose from 150 genetically characterized cancer cell lines

  • Primary material for confirmatory studies

Differences in PD-L1 gene expression between primary samples, as shown by qPCR. PD-L1 expression in samples 04 and 05 is low compared to ‘reference’ sample 01 (> 10-fold difference). Expression values are calculated using ΔΔCq method, fold change is 2^(ΔCq PS 01 -ΔCq PS 0X)
Differences in PD-L1 gene expression between primary samples, as shown by qPCR. PD-L1 expression in samples 04 and 05 is low compared to ‘reference’ sample 01 (> 10-fold difference).

Downstream Signalling Responses in Cancer Cell Lines and Primary Material

A typical workflow consists of 1. selection of cell lines; 2. generation of knock down cell lines; 3. assays to determine drug activity; 4. confirmation in primary material.

Modulation of Biological Pathways and Target Proteins

Our cancer biologists and immunologists are in close contact with the sponsor to determine the most suitable assay format for the study and share scientific insights.

PD-L1 expression in Primary Sample, TP53 Mutant
Analysis of PD-L1 protein expression by flowcytometry.
A: Primary sample, TP53 mutant; B: Primary sample, TP53 wild type, NRAS mutant; C: Cancer cell line SKOV-3. The grey areas represent the isotype control.

Enhanced Discovery of Precision Oncology Drugs

It is our mission to help you find a mechanistic hypothesis before entering the clinic. We have generated science-based technologies that help you to identify the mechanism of preclinical and clinical drug candidates. Our technologies provide in vitro proof of concept in the preparation of in vivo studies and clinical trials.

Deliverables For You

We deliver reproducible results that are adapted to your specific needs with a short delivery time. Direct contacts between the sponsor and our staff result in efficient scientific and technical support. We provide cost-free consultation on next steps in research if desired by the sponsor.

Quality. Flexibility. Short Turnaround Time.

back to Home